T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

T-Cell Metabolism, Immunodeficiency and Human Disease

Adoptive T Cell Therapy Applications

CAR-T Cell Toxicity and Safety Profiles

Feeder-free TIL expansion system makes advanced cancer immunotherapy safer

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

3 Jul 2026

Engineered CAR T cells show promise against myeloproliferative neoplasms

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, in new research led by UCL and University of Oxford researchers.

1 Jul 2026

New bacterial enzyme blueprint could accelerate cancer treatment development

A team of researchers at the University of Warwick and Monash University has solved a puzzle that's stumped drug developers for decades: how bacteria naturally create multiple versions of powerful cancer therapies.

1 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026

Dual-target CAR-T therapy shows promise against aggressive brain tumors

Researchers at McMaster University have developed a new cancer immunotherapy strategy that can simultaneously attack deadly brain tumors and the immune cells that help them grow.

1 Jul 2026

Probiotic metabolite found to suppress melanoma tumor growth in mice

Immune checkpoint inhibitors like anti-PD-1 have transformed melanoma treatment, yet more than half of patients fail to respond or eventually develop resistance.

30 Jun 2026

First-in-human trial tests safer T-cell therapy for pediatric brain cancers

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors.

30 Jun 2026

New schistosomiasis vaccine induces robust immune memory responses

For a vaccine to be effective, it must do two things. First, it must trigger an immune response. Second, the vaccine must train the body to remember the response so it can fight that same disease in the future.

29 Jun 2026

AI-driven approach identifies promising new target for CAR T cell therapy

Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that firmly centers scientists' expertise to find viable target antigens for CAR T cell therapy.

25 Jun 2026

Artificial intelligence helps breast cancer patients avoid unnecessary chemotherapy

Research led by RCSI University of Medicine and Health Sciences and University College Dublin (UCD) has identified immune markers that could help doctors more accurately determine which breast cancer patients are unlikely to benefit from chemotherapy, potentially sparing some patients from unnecessary treatment.

23 Jun 2026

New vaccines successfully boost frontline immune cells against HIV

T-cells are the immune system's frontline defenders with a crucial role in controlling HIV. In a milestone clinical trial published in the Journal of Clinical Investigation, researchers with the UNC Institute for Global Health and Infectious Diseases (IGHID) at the UNC School of Medicine have demonstrated that new vaccines can significantly boost T cells targeting the most vulnerable, conserved regions of HIV-areas considered key to effective immune control.

22 Jun 2026

New method generates renewable supply of progenitor immune cells

In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages.

19 Jun 2026

Dr. Dan Landau receives Lotus Award for ovarian cancer research

Dr. Dan Landau, the Bibliowicz Family Professor of Medicine, and a member of the Sandra and Edward Meyer Cancer Center and the Englander Institute for Precision Medicine at Weill Cornell Medicine, has received a Lotus Award from the Pershing Square Foundation for research aimed at uncovering new immunotherapy targets in ovarian cancer.

15 Jun 2026

Blocking a specific protein improves CAR T-cell therapy success in patients with blood cancers

University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.

15 Jun 2026

Dual-target CAR T therapy triggers broad immune response in brain cancer

Dual-target CAR T cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes and longer overall survival.

15 Jun 2026

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

The University of Oklahoma has received an $11.5 million award from the National Institutes of Health to establish the Oklahoma Center of ImmunoEngineering, a new research center designed to accelerate the study and treatment of diseases rooted in the immune system.

12 Jun 2026

Researchers uncover immune loop driving Sjögren's disease progression

Sjögren's disease is a widespread chronic autoimmune disorder that attacks the body's own glands, yet its underlying disease mechanisms remain poorly understood.

10 Jun 2026

Laverock Therapeutics reports key oncology research milestones

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its T-cell and macrophage oncology programs for solid tumor indications.

From Laverock Therapeutics 10 Jun 2026

AI-designed molecular switch uses caffeine to control engineered cells

For many of us, a warm cup of coffee is how we start our day. For Texas A&M Health researchers, it may also offer a new way to control engineered cells in future medicines.

8 Jun 2026